AU2021225872A1 - HLA class II-restricted T cell receptors against RAS with G12V mutation - Google Patents

HLA class II-restricted T cell receptors against RAS with G12V mutation Download PDF

Info

Publication number
AU2021225872A1
AU2021225872A1 AU2021225872A AU2021225872A AU2021225872A1 AU 2021225872 A1 AU2021225872 A1 AU 2021225872A1 AU 2021225872 A AU2021225872 A AU 2021225872A AU 2021225872 A AU2021225872 A AU 2021225872A AU 2021225872 A1 AU2021225872 A1 AU 2021225872A1
Authority
AU
Australia
Prior art keywords
seq
amino acid
acid sequence
chain
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021225872A
Other languages
English (en)
Inventor
Noam LEVIN
Biman C. PARIA
Steven A. Rosenberg
Rami Yoseph
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of AU2021225872A1 publication Critical patent/AU2021225872A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
AU2021225872A 2020-02-26 2021-02-26 HLA class II-restricted T cell receptors against RAS with G12V mutation Pending AU2021225872A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062981856P 2020-02-26 2020-02-26
US62/981,856 2020-02-26
PCT/US2021/019775 WO2021173902A1 (en) 2020-02-26 2021-02-26 Hla class ii-restricted t cell receptors against ras with g12v mutation

Publications (1)

Publication Number Publication Date
AU2021225872A1 true AU2021225872A1 (en) 2022-09-15

Family

ID=74885105

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021225872A Pending AU2021225872A1 (en) 2020-02-26 2021-02-26 HLA class II-restricted T cell receptors against RAS with G12V mutation

Country Status (12)

Country Link
US (1) US20230159614A1 (enExample)
EP (1) EP4110804A1 (enExample)
JP (1) JP7742354B2 (enExample)
KR (1) KR20220143939A (enExample)
CN (1) CN115244075A (enExample)
AU (1) AU2021225872A1 (enExample)
BR (1) BR112022016661A2 (enExample)
CA (1) CA3169086A1 (enExample)
GB (1) GB2610069B (enExample)
MX (1) MX2022010157A (enExample)
TW (1) TWI900533B (enExample)
WO (1) WO2021173902A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240000834A1 (en) * 2020-11-24 2024-01-04 Shanghai GenBase Biotechnology Co., Ltd. Ras mutant epitope peptide and t cell receptor recognizing ras mutant
WO2022183167A1 (en) 2021-02-25 2022-09-01 Alaunos Therapeutics, Inc. Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
WO2022233956A1 (en) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
US20250145950A1 (en) 2022-02-01 2025-05-08 Alaunos Therapeutics, Inc. Methods for Activation and Expansion of T Cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
KR20250037592A (ko) 2017-09-20 2025-03-17 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 돌연변이된 ras에 대한 hla 클래스 ii-제한된 t 세포 수용체
CR20200287A (es) * 2017-12-04 2020-11-11 Us Health Receptores de células t restringidos a antígeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado
WO2019129892A1 (en) * 2017-12-29 2019-07-04 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft T cell receptors for tumor specific proteasome splice variants and uses thereof
GB201804724D0 (en) * 2018-03-23 2018-05-09 Univ Oslo Hf Method of diagnosing cceliac disease
WO2019231326A1 (en) * 2018-05-31 2019-12-05 ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n.LUMC) Teipp neoantigens and uses thereof
WO2022183167A1 (en) * 2021-02-25 2022-09-01 Alaunos Therapeutics, Inc. Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof

Also Published As

Publication number Publication date
CN115244075A (zh) 2022-10-25
EP4110804A1 (en) 2023-01-04
KR20220143939A (ko) 2022-10-25
GB2610069A (en) 2023-02-22
BR112022016661A2 (pt) 2022-10-11
GB2610069B (en) 2025-04-16
US20230159614A1 (en) 2023-05-25
TWI900533B (zh) 2025-10-11
JP7742354B2 (ja) 2025-09-19
WO2021173902A1 (en) 2021-09-02
GB202212195D0 (en) 2022-10-05
CA3169086A1 (en) 2021-09-02
MX2022010157A (es) 2022-10-18
TW202140537A (zh) 2021-11-01
JP2023527613A (ja) 2023-06-30

Similar Documents

Publication Publication Date Title
US20230080742A1 (en) Hla class i-restricted t cell receptors against ras with g12d mutation
JP7742354B2 (ja) Ｇ１２ｖ変異を有するｒａｓに対するｈｌａクラスｉｉ拘束性ｔ細胞受容体
WO2021163477A1 (en) Hla class i-restricted t cell receptors against ras with g12v mutation
EP3870603A1 (en) Hla-a3-restricted t cell receptors against mutated ras
US12448428B2 (en) HLA class II-restricted t cell receptors against RAS with G12R mutation
US20230272038A1 (en) Hla class ii-restricted drb t cell receptors against ras with g12d mutation
EP4182029B1 (en) HLA-restricted class II DRB T lymphocyte receptors directed against RAS, including a G12V mutation
US20230321240A1 (en) T cell receptors recognizing r273c or y220c mutations in p53
EP4326751A1 (en) Hla class i-restricted t cell receptors against ras with q61k mutation